Rozlytrek (Entrectinib) Patent Expiration, LOE Window & CMS Spending

Rozlytrek (Entrectinib) by Roche / Genentech: FDA Orange Book core substance LOE 2037-05-18 (last listed 2038-07-18), 0 AB generics, $25.3M 2024 CMS Part D & Medicaid spend, and $4,676 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRoche / Genentech
FDA Application & PathwayN212725 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2037-05-18
Last Listed Patent or Exclusivity Date2038-07-18
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$25.3M
2024 Medicare Part D Spend$19.1M
2024 Medicaid Spend$6.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,676 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.